Intracranial hemorrhage (ICH) is a type of bleeding within the skull that can lead to severe brain damage and is considered a neurological emergency. As per Tsong-Hai Lee et al., 2024, ICH accounts for approximately 10-20% of all strokes. The growing focus on targeted intracranial hemorrhage therapeutics is driving innovation in treatment strategies. According to the intracranial hemorrhage pipeline analysis by Expert Market Research, various drug candidates are in development, including neuroprotective agents and anti-inflammatory drugs. With increasing prevalence and limited current treatment options, the market for ICH therapies is projected to grow significantly in the coming years.
Major companies involved in the intracranial hemorrhage pipeline analysis include Alexion Pharmaceuticals, Inc., Orion Corporation, and others.
Leading drugs currently in the pipeline include MW189, Autologous BMSCs + HUFF-01, TNK, and others.
The pipeline for intracranial hemorrhage is expected to grow due to rising clinical trials for neuroprotective agents, increased R&D funding, and advancements in targeted thrombolytic and anti-inflammatory therapies.
The Intracranial Hemorrhage Pipeline Analysis Report by Expert Market Research gives comprehensive insights into intracranial hemorrhage therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for intracranial hemorrhage. The intracranial hemorrhage report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The intracranial hemorrhage pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with intracranial hemorrhage treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to intracranial hemorrhage.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Intracranial hemorrhage (ICH) is a life-threatening condition where bleeding occurs within the brain tissue or surrounding areas due to ruptured blood vessels. It often results from head trauma, uncontrolled hypertension, or aneurysm rupture, leading to increased intracranial pressure and damage to brain structures. Symptoms include sudden headache, weakness, confusion, and loss of consciousness.
Intracranial hemorrhage treatment focuses on stabilizing the patient, reducing intracranial pressure, controlling blood pressure, and preventing further bleeding through medications, surgical intervention, or minimally invasive techniques based on severity. In March 2024, a clinical study in Zhejiang, China, demonstrated that nimodipine significantly improved neurological function, reduced hematoma volume, and lowered intracranial pressure in hypertensive cerebral hemorrhage patients, showing high efficacy with minimal side effects.
According to Tsong-Hai Lee et al., 2024, intracerebral hemorrhage (ICH) accounts for 27.9% of all strokes globally. Low- and middle-income countries show a higher ICH incidence than high-income countries. The estimated incidence is 8-15% in the United States, United Kingdom, and Australia, while 18-24% in Japan, Taiwan, and Korea. In the United States, the ICH rate is about 1.6 times higher among Black and Mexican American populations than White individuals. It remains a significant health burden, particularly in developing regions.
This section of the report covers the analysis of intracranial hemorrhage drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total intracranial hemorrhage clinical trials, with 44%. It is followed by phase III at 26%, phase IV at 16%, and phase I at 14%. This strong distribution across clinical phases reflects a robust development landscape. Advancements in each phase are expected to drive innovation and improve treatment options, positively influencing market growth.
The drug molecule categories covered under the intracranial hemorrhage pipeline analysis include small molecules, monoclonal antibodies, peptides, polymers, and gene therapies. The intracranial hemorrhage report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for intracranial hemorrhage. Recombinant activated Factor VII (rFVIIa) is being investigated as a hemostatic agent in the treatment of acute intracerebral hemorrhage. For instance, in the Phase III FASTEST Trial, rFVIIa was administered within 120 minutes of stroke onset to limit hematoma expansion and improve neurological outcomes. This drug class aims to enhance clot formation and stabilize bleeding sites in the brain.
The EMR report for the intracranial hemorrhage pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed intracranial hemorrhage therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in intracranial hemorrhage clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for intracranial hemorrhage. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of intracranial hemorrhage drug candidates.
MW189 is being evaluated in a Phase 2a trial, sponsored by Johns Hopkins University and is assessing safety and tolerability in patients with intracerebral hemorrhage. MW189, a novel small-molecule suppressor of injury-induced proinflammatory cytokine overproduction, attenuates cerebral edema and improves functional outcomes in preclinical ICH models.
Hokkaido University Hospital is developing HUFF-01 for chronic intracerebral hemorrhage. This Phase I/II trial aims to evaluate the safety and efficacy of intracerebral transplantation of autologous bone marrow stromal cells (BMSCs), combined with a recombinant peptide scaffold. HUFF-01, composed of 50 million BMSCs and RCP m-piece scaffold, is being stereotactically delivered to enhance cell survival, integration, and functional recovery in affected brain tissue.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Intracranial Hemorrhage Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for intracranial hemorrhage. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into intracranial hemorrhage collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share